Logo image of ELUT

ELUTIA INC (ELUT) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ELUT - US05479K1060 - Common Stock

0.6886 USD
-0.03 (-4.76%)
Last: 1/12/2026, 8:00:02 PM
0.7 USD
+0.01 (+1.66%)
Pre-Market: 1/13/2026, 4:05:41 AM
Fundamental Rating

1

Overall ELUT gets a fundamental rating of 1 out of 10. We evaluated ELUT against 528 industry peers in the Biotechnology industry. ELUT may be in some trouble as it scores bad on both profitability and health. ELUT has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ELUT had negative earnings in the past year.
ELUT had a negative operating cash flow in the past year.
ELUT had negative earnings in each of the past 5 years.
ELUT had a negative operating cash flow in each of the past 5 years.
ELUT Yearly Net Income VS EBIT VS OCF VS FCFELUT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

ELUT has a Return On Assets of -90.02%. This is in the lower half of the industry: ELUT underperforms 72.54% of its industry peers.
Industry RankSector Rank
ROA -90.02%
ROE N/A
ROIC N/A
ROA(3y)-94.61%
ROA(5y)-70.28%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ELUT Yearly ROA, ROE, ROICELUT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 1K -1K -2K -3K -4K

1.3 Margins

Looking at the Gross Margin, with a value of 45.97%, ELUT is in the better half of the industry, outperforming 74.62% of the companies in the same industry.
In the last couple of years the Gross Margin of ELUT has remained more or less at the same level.
ELUT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 45.97%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.05%
GM growth 5Y-0.95%
ELUT Yearly Profit, Operating, Gross MarginsELUT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150 -200

More info and screens

0

2. Health

2.1 Basic Checks

ELUT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ELUT has more shares outstanding
ELUT has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ELUT has a worse debt to assets ratio.
ELUT Yearly Shares OutstandingELUT Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
ELUT Yearly Total Debt VS Total AssetsELUT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -14.14, we must say that ELUT is in the distress zone and has some risk of bankruptcy.
ELUT's Altman-Z score of -14.14 is on the low side compared to the rest of the industry. ELUT is outperformed by 78.41% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -14.14
ROIC/WACCN/A
WACC14.16%
ELUT Yearly LT Debt VS Equity VS FCFELUT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M

2.3 Liquidity

A Current Ratio of 0.44 indicates that ELUT may have some problems paying its short term obligations.
The Current ratio of ELUT (0.44) is worse than 90.72% of its industry peers.
A Quick Ratio of 0.40 indicates that ELUT may have some problems paying its short term obligations.
ELUT has a worse Quick ratio (0.40) than 90.91% of its industry peers.
Industry RankSector Rank
Current Ratio 0.44
Quick Ratio 0.4
ELUT Yearly Current Assets VS Current LiabilitesELUT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

2

3. Growth

3.1 Past

ELUT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 73.95%, which is quite impressive.
ELUT shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -33.02%.
ELUT shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -10.69% yearly.
EPS 1Y (TTM)73.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.73%
Revenue 1Y (TTM)-33.02%
Revenue growth 3Y-19.88%
Revenue growth 5Y-10.69%
Sales Q2Q%-43.89%

3.2 Future

Based on estimates for the next years, ELUT will show a very strong growth in Earnings Per Share. The EPS will grow by 22.61% on average per year.
Based on estimates for the next years, ELUT will show a decrease in Revenue. The Revenue will decrease by -8.34% on average per year.
EPS Next Y81.62%
EPS Next 2Y33.85%
EPS Next 3Y22.61%
EPS Next 5YN/A
Revenue Next Year-24.6%
Revenue Next 2Y-21.45%
Revenue Next 3Y-8.34%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ELUT Yearly Revenue VS EstimatesELUT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 10M 20M 30M 40M 50M
ELUT Yearly EPS VS EstimatesELUT Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 -2 -4 -6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ELUT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ELUT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ELUT Price Earnings VS Forward Price EarningsELUT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ELUT Per share dataELUT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

ELUT's earnings are expected to grow with 22.61% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.85%
EPS Next 3Y22.61%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ELUT!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

ELUTIA INC

NASDAQ:ELUT (1/12/2026, 8:00:02 PM)

Premarket: 0.7 +0.01 (+1.66%)

0.6886

-0.03 (-4.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-09 2025-11-09/bmo
Earnings (Next)03-04 2026-03-04/amc
Inst Owners39.76%
Inst Owner ChangeN/A
Ins Owners2.92%
Ins Owner Change8.36%
Market Cap29.40M
Revenue(TTM)21.08M
Net Income(TTM)-26.47M
Analysts82.5
Price Target3.57 (418.44%)
Short Float %0.31%
Short Ratio0.25
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.22%
Min EPS beat(2)-32.64%
Max EPS beat(2)43.07%
EPS beat(4)2
Avg EPS beat(4)15.16%
Min EPS beat(4)-32.64%
Max EPS beat(4)52.18%
EPS beat(8)3
Avg EPS beat(8)-32.92%
EPS beat(12)5
Avg EPS beat(12)-27.63%
EPS beat(16)6
Avg EPS beat(16)-23.29%
Revenue beat(2)0
Avg Revenue beat(2)-28.63%
Min Revenue beat(2)-51.01%
Max Revenue beat(2)-6.26%
Revenue beat(4)0
Avg Revenue beat(4)-19.38%
Min Revenue beat(4)-51.01%
Max Revenue beat(4)-6.26%
Revenue beat(8)1
Avg Revenue beat(8)-12.66%
Revenue beat(12)2
Avg Revenue beat(12)-9.2%
Revenue beat(16)4
Avg Revenue beat(16)-6.52%
PT rev (1m)0%
PT rev (3m)-36.36%
EPS NQ rev (1m)11.11%
EPS NQ rev (3m)11.11%
EPS NY rev (1m)16.04%
EPS NY rev (3m)25.83%
Revenue NQ rev (1m)10.71%
Revenue NQ rev (3m)-65.17%
Revenue NY rev (1m)-6.27%
Revenue NY rev (3m)-23.2%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.39
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.68
EYN/A
EPS(NY)-0.52
Fwd EYN/A
FCF(TTM)-0.79
FCFYN/A
OCF(TTM)-0.76
OCFYN/A
SpS0.49
BVpS-1.03
TBVpS-1.07
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -90.02%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 45.97%
FCFM N/A
ROA(3y)-94.61%
ROA(5y)-70.28%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.05%
GM growth 5Y-0.95%
F-Score3
Asset Turnover0.72
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 33.32%
Cap/Sales 5.29%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.44
Quick Ratio 0.4
Altman-Z -14.14
F-Score3
WACC14.16%
ROIC/WACCN/A
Cap/Depr(3y)14.22%
Cap/Depr(5y)13.83%
Cap/Sales(3y)1.73%
Cap/Sales(5y)1.49%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)73.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.73%
EPS Next Y81.62%
EPS Next 2Y33.85%
EPS Next 3Y22.61%
EPS Next 5YN/A
Revenue 1Y (TTM)-33.02%
Revenue growth 3Y-19.88%
Revenue growth 5Y-10.69%
Sales Q2Q%-43.89%
Revenue Next Year-24.6%
Revenue Next 2Y-21.45%
Revenue Next 3Y-8.34%
Revenue Next 5YN/A
EBIT growth 1Y10.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year60.81%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-83.76%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-82.24%
OCF growth 3YN/A
OCF growth 5YN/A

ELUTIA INC / ELUT FAQ

Can you provide the ChartMill fundamental rating for ELUTIA INC?

ChartMill assigns a fundamental rating of 1 / 10 to ELUT.


Can you provide the valuation status for ELUTIA INC?

ChartMill assigns a valuation rating of 1 / 10 to ELUTIA INC (ELUT). This can be considered as Overvalued.


Can you provide the profitability details for ELUTIA INC?

ELUTIA INC (ELUT) has a profitability rating of 1 / 10.


How financially healthy is ELUTIA INC?

The financial health rating of ELUTIA INC (ELUT) is 0 / 10.